ArticleCell reports2017
OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts.
Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Low-Intensity Electric Field Stimulation Modulates Proliferation, Stemness, and Chondrogenesis of Tonsil-Derived Mesenchymal Stem Cells.Tissue engineering and regenerative medicine · 2026Article
- Enhanced Activities of OCT4 and SOX2 Promote Epigenetic Reprogramming by Shortening G1 Phase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Gene therapy strategies for aging intervention.Cell insight · 2025Review
- X-Linked Gene Dosage and SOX2 Act as Key Roadblocks for Human Germ Cell Specification in Klinefelter Syndrome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells.International journal of molecular sciences · 2024Review
- Correlation analysis of cancer stem cell marker CD133 and human endogenous retrovirus (HERV)-K env in SKOV3 ovarian cancer cells.Genes & genomics · 2024Article
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming.Nature aging · 2024Review
- PC3T: a signature-driven predictor of chemical compounds for cellular transition.Communications biology · 2023Article
- Evaluation of the determinants for improved pluripotency induction and maintenance by engineered SOX17.Nucleic acids research · 2023Article
- Spermidine Retarded the Senescence of Multipotent Mesenchymal Stromal CellsStem cells international · 2023Article
- Article
- The 9aaTAD Activation Domains in the Yamanaka Transcription Factors Oct4, Sox2, Myc, and Klf4.Stem cell reviews and reports · 2021Article
- LncRNA LINC00520 aggravates cell proliferation and migration in lung adenocarcinoma via a positive feedback loop.BMC pulmonary medicine · 2021Article
- Cellular reprogramming to model and study epigenetic alterations in cancer.Stem cell research · 2020Review
- Identification, characterization and microRNA expression profiling of side population cells in human oral squamous cell carcinoma Tca8113 cell lines.Molecular medicine reports · 2020Article
- Nanog safeguards early embryogenesis against global activation of maternal β-catenin activity by interfering with TCF factors.PLoS biology · 2020Article
- Molecular characterization of AwSox2 from bivalveInnate immunity · 2020Article
- The spatial binding model of the pioneer factor Oct4 with its target genes during cell reprogramming.Computational and structural biotechnology journal · 2019Article
- Purinergic Signaling Pathway in Human Olfactory Neuronal Precursor Cells.Stem cells international · 2019Article
- Bone marrow mesenchymal stem cells combined with Sox2 increase the functional recovery in rat with traumatic brain injury.Chinese neurosurgical journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
SOX2 and OCT4, in conjunction with KLF4 and cMYC, are sufficient to reprogram human fibroblasts to induced pluripotent stem cells (iPSCs), but it is unclear if they function as transcriptional activators or as repressors. We now show that, like OCT4, SOX2 functions as a transcriptional activator. We substituted SOX2-VP16 (a strong activator) for wild-type (WT) SOX2, and we saw an increase in the efficiency and rate of reprogramming, whereas the SOX2-HP1 fusion (a strong repressor) eliminated reprogramming. We report that, at an early stage of reprogramming, virtually all DNA-bound OCT4, SOX2, and SOX2-VP16 were embedded in putative enhancers, about half of which were created de novo. Those associated with SOX2-VP16 were, on average, stronger than those bearing WT SOX2. Many newly created putative enhancers were transient, and many transcription factor locations on DNA changed as reprogramming progressed. These results are consistent with the idea that, during reprogramming, there is an intermediate state that is distinct from both parental cells and iPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.